fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Metoclopramide HCL

All injection strengths: Limited Use (codes 481, 657)

Metoclopramide Hydrochloride Injection · DIN 02537397 · 5 mg/mL · injection solution (Preservative Free)

Limited Use, Reason for Use code 481, 657 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481, 657 required
Write on scriptone applicable Reason for Use code, 481 or 657 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 481, 657
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes. Reason for Use code 657 For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition. Coverage limit: LU Authorization Period: 1 year Coverage limit: *e.g., home care recipients, long-term care home residents.
1 brand, same coverage
Metoclopramide Hydrochloride Injection · DIN 02537397 Manufacturer: Jamp Pharma Corporation; listing date 2024-04-30 Health Canada: Marketed since 2024-02-08 · brand METOCLOPRAMIDE HYDROCHLORIDE INJECTION · ATC A03FA01 METOCLOPRAMIDE · form Solution · route Intravenous, Intramuscular · ingredients METOCLOPRAMIDE DIHYDROCHLORIDE (METOCLOPRAMIDE HYDROCHLORIDE MONOHYDRATE) 5 MG/ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Metoclopramide Hydrochloride Injection: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3748). What the ministry pays, not the patient.

Ministry pays: $2.3748 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02537397)

Source record
DIN 02537397: Metoclopramide Hydrochloride Injection Raw flags: sec12=Y, sec3=Y Item: 564000082; group id 683; item number 1701; lccId 00271; manufacturer id JPC Source form: Inj Sol (Preservative Free); strength: 5mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.3748; ministry $2.3748 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02537397 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102611
Interchangeable products
Metoclopramide HCL Injection · DIN 02185431 · $2.3748
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02537397
Shortage record checked October 6, 2026

Other products in the same Health Canada class (A03FA): coverage varies; not interchangeable

  • Domperidone (Motilium): general benefit, not a benefit
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

DOMPERIDONE MALEATE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 10mg · Tab

5-AMINOSALICYLIC ACID

· 17 products · General benefit (16), Listed, not a benefit (1) · strengths: 1g/Actuation, 500mg, 1.2g, 1g, 1g/100mL, 4g/100mL, 4g, 1000mg, 400mg · 14 Actuation-Foam Enema Canister Pk, Del-Release Tab, Delayed & ER Tab, DR Tab, Enema, Ent Tab, ER Tab, Rect Susp-Pk, Sup, Tab

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

LACTULOSE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 667mg/mL · O/L

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

OLSALAZINE SODIUM

· 1 products · General benefit · strengths: 250mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Metoclopramide Hydrochloride Injection Page 2 of 18 Metoclopramide Hydrochloride Injection is useful as an adjunct in the management of delayed gastric emptying associated with subacute and chronic gastritis and sequelæ of surgical operations such as vagotomy and pyloroplasty. Metoclopramide Hydrochloride Injection is indicated in the prophylaxis of vomiting induced by cancer chemotherapeutic regimens that include cisplatin as a component. Metoclopramide Hydrochloride Injection has been found useful as an adjunct to facilitate small bowel intubation. Metoclopramide Hydrochloride Injection is indicated for the prophylaxis of postoperative vomiting. https://pdf.hres.ca/dpd_pm/00032319.PDF PM date: November 18, 2014 Source product: METOCLOPRAMIDE HYDROCHLORIDE INJECTION; DIN 02185431; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.